Biobanking of CSF: International standardization to optimize biomarker development
Biobanking of CSF: International standardization to optimize biomarker development
复制标题
DOI：
10.1016/j.clinbiochem.2013.12.024
复制
发表时间：
2014-03-01
影响因子：
2.8
通讯作者：
Mollenhauer, Brit
中科院分区：
文献类型：
--
作者：
Teunissen, Charlotte E.;Tumani, Hayrettin;Mollenhauer, Brit
脑脊液反映了神经系统疾病的病理生理方面，迫切需要神经保护策略和生物标志物。因此，生物库对于发现和评估神经系统疾病的生物标志物是非常重要的。脑脊液生物库的重要而独特的特点是在国际网络中进行密集的合作，并严格应用标准化方案。这篇综述中介绍的脑脊液和血液采集目前采用的标准化方案使得在大量患者和对照人群中进行生物标记物研究成为可能。这篇综述的另一个主题是控制组的选择，这影响了生物标记物调查的结果。脑脊液生物库中的对照组主要由不同的疾病对照组组成。这在一定程度上是因为腰椎穿刺术大多用于临床适应症，很少仅用于研究目的，因为这是一种相对侵入性较强的操作。此外，缺乏统一的标准和对照组的定义。因此，我们对生物标记物研究中的这些对照组提出了统一的共识定义，即健康对照(HC)、脊麻受试者(SAS)、症状对照(SC)、炎症性神经疾病对照(CINDC)、周围炎症性神经疾病对照(PINDC)和非炎症性神经疾病对照(NINDC)。脑脊液生物库的另一个重要方面是质量控制。需要进行系统的研究，以解决分析前和储存变化对广泛的脑脊液蛋白的影响。综上所述，神经退行性疾病的生物标记物研究由于多个小组的协作和多中心努力而进入了一个新的时代。简化生物库程序，包括质量控制，以及为调查生物标记物选择最佳控制组，是进行高质量生物标记物研究的重要改进。(C)2014年加拿大临床化学家学会。爱思唯尔公司出版，版权所有。
Cerebrospinal fluid (CSF) reflects pathophysiological aspects of neurological diseases, where neuroprotective strategies and biomarkers are urgently needed. Therefore, biobanking is very relevant for biomarker discovery and evaluation of neurological diseases. Important and unique features of CSF biobanking are intensive collaboration in international networks and the tight application of standardized protocols. The current adoption of standardized protocols for CSF and blood collection as presented in this review enables biomarker studies in large cohorts of patients and controls. Another topic of this review is the selection of control groups, which influences the outcome of biomarker investigations. Control groups in CSF biobanks mainly consist of different disease controls. This is in part due to the fact that lumbar punctures are mostly performed for clinical indications and rarely for research purposes only, as it is a relatively invasive procedure. Moreover, there is a lack of homogenous criteria and definition of control groups. We therefore propose uniform consensus definitions for such control groups in biomarker research, i.e. Healthy controls (HC), Spinal anesthesia subjects (SAS), Symptomatic controls (SC), Inflammatory Neurological Disease Controls (CINDC), Peripheral Inflammatory Neurological Disease Controls (PINDC) and Non-inflammatory Neurological Disease Controls (NINDC). Another important aspect of CSF biobanking is quality control. Systematic studies to address effects of pre-analytical and storage variation on a broad range of CSF proteins are needed.In conclusion, biomarker research in neurodegenerative diseases has entered a new era due to the collaborative and multicenter efforts of many groups. The streamlining of biobanking procedures, including quality control, and the selection of optimal control groups for investigating biomarkers are important improvements to perform high quality biomarker studies. (C) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.